ClinicalTrials.gg
CompletedNCT04456699Updated Oct 29, 2024Results posted

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

A Phase 3 interventional study of Olaparib and 5-FU in Metastatic Colorectal Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 129 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
335
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Enrollment
31st of 224
335 · median 63
Started
2020
with 9 others
Phase 3
42 of 230
4 open now
Registered
168th of 230
by date

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 31st largest by enrollment of the 224 interventional ones that give a count, is one of 10 that started in 2020, is one of 42 in phase 3, and was the 168th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with a fluoropyrimidine in participants with unresectable or metastatic colorectal cancer who have not progressed following first-line induction. The primary hypotheses are: Olaparib + Bevacizumab is superior to a fluoropyrimidine + Bevacizumab with respect to progression-free survival (PFS) using Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR); Olaparib is superior to a fluoropyrimidine + Bevacizumab with respect to PFS using RECIST 1.1 as assessed by BICR. As of amendment 5 study enrollment is being discontinued and study participants randomized to one of the two experimental arms (olaparib plus bevacizumab or olaparib monotherapy) must discontinue study intervention. Participants who are still on study treatment will no longer have tumor response assessments by BICR.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • colorectal cancer
  • CRC
  • Olaparib
  • Bevacizumab
  • FOLFOX
  • 5-FU
  • fluorouracil
  • folinic acid
  • oxaliplatin
  • CAPOX
  • capecitabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a -confirmed or unresectable (Stage IV as defined by American Joint Committee on Cancer (AJCC eighth edition) colorectal adenocarcinoma (National Comprehensive Cancer Network [NCCN] 2018).
  2. Has not progressed (ie, achieved a stable disease [SD], partial response [PR], or complete response [CR]) after a induction course of at least 6 cycles of folinic acid/fluorouracil/oxaliplatin (FOLFOX) + bevacizumab or 4 cycles of capecitabine and oxaliplatin (CAPOX) + bevacizumab as first-line therapy.

    • Participants must not have received an agent during their induction course.
    • Determination of best overall response (SD/PR/CR) will be made by the investigator.
    • Non-Progressive Disease (PD) will be verified by BICR prior to randomization based on the images submitted to imaging contract research organization (iCRO) as described in inclusion criterion 4.
    • "First-line therapy" is defined as the first systemic chemotherapy regimen given for the diagnosis of unresectable or metastatic colorectal cancer (CRC). Participants may have received prior /neoadjuvant chemotherapy for CRC, as long as it was completed at least 6 months prior to initiation of first-line CAPOX + bevacizumab or FOLFOX + bevacizumab induction treatment.
  3. Has experienced unacceptable toxicity to oxaliplatin that, in the opinion of the treating physician, requires/required the discontinuation of oxaliplatin. Note: As an example, unacceptable toxicity may include (but is not limited to) severe or prolonged neurotoxicity.

    • Participants must be randomized within a minimum of 2 weeks and a maximum of 6 weeks after their last dose of CAPOX + bevacizumab or FOLFOX + bevacizumab (last dose is the day of the last infusion that contained oxaliplatin).
  4. Has provided to the iCRO 1 set of baseline radiographic images taken before or during the CAPOX + bevacizumab or FOLFOX + bevacizumab induction period and at least 42 days prior to the imaging performed during Screening. Tumor imaging at Screening must be performed within 28 days prior to the date of randomization.
  5. Has an (ECOG) performance status of 0 to 1 within 10 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

  1. Has known to the components and/or in bevacizumab, 5-FU, capecitabine, or olaparib.
  2. Has known active central nervous system (CNS) and/or carcinomatous meningitis. Participants with previously treated may participate provided they are radiologically stable (ie, without evidence of progression for at least 28 days by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of intervention for at least 14 days prior to first dose of study intervention.
  3. Has an active infection requiring systemic therapy.
  4. Has a known history of (HIV) infection. No HIV testing is required unless mandated by local health authority.
  5. Has a known history of or is positive for surface antigen (HBsAg reactive) or ribonucleic acid (HCV RNA [qualitative]) is detected). Note: No testing for hepatitis B and hepatitis C is required unless mandated by local health authority.
  6. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  7. Has myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) or with features suggestive of MDS/AML.
  8. Has hemoptysis or hematemesis within 28 days prior to randomization.
  9. Has evidence of bleeding diathesis or significant coagulopathy (in the absence of anticoagulation).
  10. Has bleeding within 28 days prior to randomization.
  11. Is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high-resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining .
  12. Has 1 or more conditions that, in the opinion of the treating physician, make the participant ineligible for treatment with bevacizumab. These conditions may include:

    • Uncontrolled hypertension (systolic blood pressure [SBP] >150 mm Hg or diastolic blood pressure [DBP] >100 mm Hg) or a history of hypertensive crisis or hypertensive encephalopathy
    • Arterial thromboembolic events (eg, myocardial infarction, cerebral infarction)
    • History of nephrotic syndrome or moderate proteinuria
    • History of gastrointestinal perforation
    • History of non-gastrointestinal fistula formation
    • History of possible reversible encephalopathy syndrome (RPLS)
  13. Has received prior systemic anticancer therapy (other than CAPOX + bevacizumab or FOLFOX + bevacizumab induction) including agents within 28 days prior to randomization. Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with persistent alopecia or Grade ≤3 neuropathy are eligible.
  14. Has received prior therapy with olaparib or with any other polyadenosine 5'-diphosphoribose polymerase (PARP) inhibitor.
  15. Is currently receiving either strong (eg, itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (eg, ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 3A4 () that cannot be discontinued for the duration of the study. The required prior to randomization is 2 weeks.
  16. Is currently receiving either strong (phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate (eg. bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be discontinued for the duration of the study. The required washout period prior to randomization is 5 weeks for phenobarbital and 3 weeks for other agents.
  17. Has undergone major surgery within 2 weeks of randomization or has not recovered adequately from toxicities and/or complications from any major surgery prior to randomization.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
335 participants (actual)

Study arms

  • Experimental
    Olaparib + bevacizumab

    Participants will receive olaparib (300 mg twice daily \[BID\] oral) + Bevacizumab (5 mg/kg intravenous \[IV\] once every 2 weeks \[Q2W\]) until progressive disease or end of study.

    Drug: Olaparib · Drug: Bevacizumab

  • Experimental
    Olaparib

    Participants will receive olaparib (300 mg BID) oral, until progressive disease or end of study.

    Drug: Olaparib

  • Active comparator
    Bevacizumab + chemotherapy

    Participants will receive investigator's choice of either bevacizumab (7.5 mg/kg IV once every three weeks (Q3W)) + capecitabine (1000 mg/m\^2 BID for 14 days, then 7 days off, Q3W) or bevacizumab (5 mg/kg IV Q2W) + 5-FU (2400 mg/m2 IV over 46 to 48 hours Q2W; bolus 5-FU (400 mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion). Leucovorin or levoleucovorin 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) Q2W IV infusion may be added per investigator's discretion. Treatment will continue until progressive disease or end of study.

    Drug: 5-FU · Drug: Bevacizumab · Drug: Capecitabine · Drug: Leucovorin/ levoleucovorin

Interventions

  • 300 mg BID, oral until progressive disease or end of study

    Also known as: LYNPARZA^TM

  • Drug5-FU

    2400 mg/m\^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5-FU (400mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion

    Also known as: Fluorouracil, Adrucil, Efudex

  • 5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study

    Also known as: MVASI^TM, Avastin

  • 1000 mg/m\^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study

    Also known as: XELODA^®

  • DrugLeucovorin/ levoleucovorin

    Drug pages: Leucovorin · Levoleucovorin

    400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study

    Also known as: Folinic Acid, Fusilev^®, Khapzory^TM

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. PFS using RECIST 1.1 as assessed by BICR is presented.

    Time frame: Up to approximately 30 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. The OS is presented.

    Time frame: Up to approximately 30 months

  2. Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR

    ORR was defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to approximately 30 months

  3. Number of Participants With One or More Adverse Events (AE)

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced at least one AE was reported for each arm.

    Time frame: Up to approximately 30 months

  4. Number of Participants Discontinuing Study Intervention Due to an AE

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study intervention due to an AE was reported for each arm.

    Time frame: Up to approximately 30 months

  5. Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. DOR is defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis will be censored at the date of their last tumor assessment. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions is also considered PD. DOR assessments will be based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experience a confirmed CR or PR will be presented.

    Time frame: Up to approximately 30 months

07

Results

Posted Apr 2, 2024

Participant flow

Participant flow — Overall Study
MilestoneOlaparib + BevacizumabOlaparibBevacizumab + Chemotherapy
Started111115109
Treated111113108
Completed000
Not completed111115109
Withdrew: Death485052
Withdrew: Physician decision002
Withdrew: Sponsor decision556150
Withdrew: Withdrawal by subject845

Outcome measures

PrimaryProgression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. PFS using RECIST 1.1 as assessed by BICR is presented.

Time frame:
Up to approximately 30 months
Reported as:
Median · Months
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
MonthsOlaparib + BevacizumabOlaparibBevacizumab + Chemotherapy
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)3.7 (3.4 to 5.3)3.6 (2.0 to 3.7)5.5 (3.8 to 5.6)
Statistical analysis
  • Olaparib + Bevacizumab vs Bevacizumab + Chemotherapy · Log Rank · p = 0.9774 · Hazard ratio (hr): 1.41 · 95% CI 1.00 to 1.97Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior FOLFOX/CAPOX + Bev induction response, number of induction cycles and mutation status.
  • Olaparib vs Bevacizumab + Chemotherapy · Log Rank · p = 0.9993 · Hazard ratio (hr): 1.75 · 95% CI 1.23 to 2.49Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior FOLFOX/CAPOX + Bev induction response, number of induction cycles and mutation status.
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. The OS is presented.

Time frame:
Up to approximately 30 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsOlaparib + BevacizumabOlaparibBevacizumab + Chemotherapy
Overall Survival (OS)21.2 (15.1 to NA)21.6 (17.2 to NA)19.9 (13.8 to 22.5)
Statistical analysis
  • Olaparib + Bevacizumab vs Bevacizumab + Chemotherapy · Log Rank · p = 0.1527 · Hazard ratio (hr): 0.81 · 95% CI 0.54 to 1.21Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior FOLFOX/CAPOX + Bev induction response, number of induction cycles and mutation status.
  • Olaparib vs Bevacizumab + Chemotherapy · Log Rank · p = 0.2491 · Hazard ratio (hr): 0.87 · 95% CI 0.59 to 1.30Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior FOLFOX/CAPOX + Bev induction response, number of induction cycles and mutation status.
SecondaryObjective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR

ORR was defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to approximately 30 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR
Percentage of ParticipantsOlaparib + BevacizumabOlaparibBevacizumab + Chemotherapy
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR4.8 (1.6 to 10.9)1.9 (0.2 to 6.6)4.8 (1.6 to 10.8)
Statistical analysis
  • Olaparib + Bevacizumab vs Bevacizumab + Chemotherapy · Miettinen and Nurminen · p = 0.5272 · Difference in percentage: -0.2 · 95% CI -7.0 to 6.5Based on Miettinen \& Nurminen method stratified by prior FOLFOX/CAPOX + Bev induction response, cycles and mutation status.
  • Olaparib vs Bevacizumab + Chemotherapy · Miettinen & Nurminen · p = 0.9020 · Difference in percentage: -3.2 · 95% CI -9.7 to 2.3Based on Miettinen \& Nurminen method stratified by prior FOLFOX/CAPOX + Bev induction response, cycles and mutation status.
SecondaryNumber of Participants With One or More Adverse Events (AE)

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced at least one AE was reported for each arm.

Time frame:
Up to approximately 30 months
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events (AE)
ParticipantsOlaparib + BevacizumabOlaparibBevacizumab + Chemotherapy
Number of Participants With One or More Adverse Events (AE)1019196
SecondaryNumber of Participants Discontinuing Study Intervention Due to an AE

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study intervention due to an AE was reported for each arm.

Time frame:
Up to approximately 30 months
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Intervention Due to an AE
ParticipantsOlaparib + BevacizumabOlaparibBevacizumab + Chemotherapy
Number of Participants Discontinuing Study Intervention Due to an AE647
SecondaryDuration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. DOR is defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis will be censored at the date of their last tumor assessment. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions is also considered PD. DOR assessments will be based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experience a confirmed CR or PR will be presented.

Time frame:
Up to approximately 30 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
MonthsOlaparib + BevacizumabOlaparibBevacizumab + Chemotherapy
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICRNA (3.6 to NA)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over Up to approximately 38 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib + Bevacizumab49/111 (44.1%)16/111 (14.4%)94/111 (84.7%)
Olaparib51/115 (44.3%)13/113 (11.5%)74/113 (65.5%)
Bevacizumab + Chemotherapy52/109 (47.7%)14/108 (13%)86/108 (79.6%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventOlaparib + BevacizumabOlaparibBevacizumab + Chemotherapy
Upper gastrointestinal haemorrhageGastrointestinal disorders0/1110/1132/108
Rectal haemorrhageGastrointestinal disorders0/1112/1130/108
Acute coronary syndromeCardiac disorders0/1110/1131/108
Atrial fibrillationCardiac disorders0/1110/1131/108
Myocardial infarctionCardiac disorders0/1110/1131/108
DiarrhoeaGastrointestinal disorders0/1110/1131/108
Duodenal stenosisGastrointestinal disorders0/1110/1131/108
EnteritisGastrointestinal disorders0/1110/1131/108
Intestinal obstructionGastrointestinal disorders1/1111/1131/108
Large intestinal obstructionGastrointestinal disorders0/1110/1131/108
Most frequent other events
Showing 10 of 32
Most frequent other events
EventOlaparib + BevacizumabOlaparibBevacizumab + Chemotherapy
AnaemiaBlood and lymphatic system disorders32/11121/1138/108
NauseaGastrointestinal disorders31/11123/11324/108
Abdominal painGastrointestinal disorders19/1118/11313/108
Decreased appetiteMetabolism and nutrition disorders15/11118/11312/108
ConstipationGastrointestinal disorders16/11111/11314/108
AstheniaGeneral disorders16/1118/11311/108
DiarrhoeaGastrointestinal disorders11/1119/11315/108
FatigueGeneral disorders14/11115/11310/108
VomitingGastrointestinal disorders13/1117/11311/108
StomatitisGastrointestinal disorders8/1114/11311/108

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Olaparib + BevacizumabOlaparibBevacizumab + ChemotherapyTotal
Mean59.5 ± 12.861.1 ± 10.763.2 ± 11.361.3 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib + BevacizumabOlaparibBevacizumab + ChemotherapyTotal
Female504944143
Male616665192
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olaparib + BevacizumabOlaparibBevacizumab + ChemotherapyTotal
Hispanic or Latino18161044
Not Hispanic or Latino889394275
Unknown or Not Reported56516
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olaparib + BevacizumabOlaparibBevacizumab + ChemotherapyTotal
American Indian or Alaska Native105419
Asian25403095
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White716466201
More than one race2349
Unknown or Not Reported33410
Response to Prior Induction
Response to Prior Induction(Participants)Olaparib + BevacizumabOlaparibBevacizumab + ChemotherapyTotal
CR/PR494847144
SD626762191
Number of Induction Cycles
Number of Induction Cycles(Participants)Olaparib + BevacizumabOlaparibBevacizumab + ChemotherapyTotal
6-8 cycles for FOLFOX + bevacizumab or 4-6 cycles for CAPOX + bevacizumab535753163
>8 cycles for FOLFOX + bevacizumab or >6 cycles for CAPOX + bevacizumab585856172
Mutation Status
Mutation Status(Participants)Olaparib + BevacizumabOlaparibBevacizumab + ChemotherapyTotal
BRAF and RAS all wild type32332994
BRAF or RAS Mutation798280241
08

Study locations

129 sites
  • Providence Saint Joseph Medical Center, Disney Family Cancer ( Site 1392)
    Burbank, California 91505, United States
  • St Joseph Heritage Healthcare-Oncology ( Site 1383)
    Fullerton, California 92835, United States
  • UC Health Memorial Hospital ( Site 1401)
    Colorado Springs, Colorado 80909, United States
  • Poudre Valley Health System ( Site 1402)
    Fort Collins, Colorado 80528, United States
  • University Cancer & Blood Center, LLC ( Site 1381)
    Athens, Georgia 30607, United States
  • University of Chicago ( Site 1357)
    Chicago, Illinois 60637, United States
  • Illinois Cancer Care, PC ( Site 1352)
    Peoria, Illinois 61615, United States
  • James Graham Brown Cancer Center ( Site 1393)
    Louisville, Kentucky 40202, United States
  • University Medical Center New Orleans ( Site 1365)
    New Orleans, Louisiana 70112, United States
  • New England Cancer Specialists ( Site 1422)
    Scarborough, Maine 04074, United States
  • Cancer & Hematology Centers of Western Michigan ( Site 1358)
    Grand Rapids, Michigan 49503, United States
  • Hattiesburg Clinic Hematology/Oncology ( Site 1418)
    Hattiesburg, Mississippi 39401, United States
  • Washington University in St. Louis ( Site 1384)
    Saint Louis, Missouri 63110, United States
  • St. Vincent Frontier Cancer Center-Research ( Site 1414)
    Billings, Montana 59102, United States
  • CHI Health St. Francis ( Site 1406)
    Grand Island, Nebraska 68803, United States
  • Cancer Partners of Nebraska ( Site 1353)
    Lincoln, Nebraska 68510, United States
  • Providence Portland Medical Center ( Site 1400)
    Portland, Oregon 97213, United States
  • Oregon Health & Science University ( Site 1411)
    Portland, Oregon 97232, United States
  • Allegheny Singer Research Institute ( Site 1364)
    Pittsburgh, Pennsylvania 15212, United States
  • West Cancer Center - East Campus ( Site 1396)
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center ( Site 1362)
    Nashville, Tennessee 37232, United States
  • Baylor Scott & White Medical Center - Temple ( Site 1397)
    Temple, Texas 76508, United States
  • Blue Ridge Cancer Care ( Site 1374)
    Roanoke, Virginia 24014, United States
  • St George Hospital ( Site 0052)
    Kogarah, New South Wales 2217, Australia
  • Liverpool Hospital ( Site 0055)
    Liverpool, New South Wales 2170, Australia
  • Royal Brisbane and Women s Hospital ( Site 0054)
    Herston, Queensland 4029, Australia
  • Queen Elizabeth Hospital ( Site 0053)
    Woodville South, South Australia 5011, Australia
  • Monash Health ( Site 0050)
    Clayton, Victoria 3168, Australia
  • Peninsula Health Frankston Hospital ( Site 0056)
    Frankston, Victoria 3199, Australia
  • Imelda vzw ( Site 0110)
    Bonheiden, Antwerpen 2820, Belgium
  • AZ Klina ( Site 0106)
    Brasschaat, Antwerpen 2930, Belgium
  • UZ Antwerpen ( Site 0108)
    Edegem, Antwerpen 2650, Belgium
  • UCL Saint Luc ( Site 0100)
    Brussels, Bruxelles-Capitale, Region De 1200, Belgium
  • OLV Ziekenhuis ( Site 0109)
    Aalst, Oost-Vlaanderen 9300, Belgium
  • UZ Gent ( Site 0101)
    Gent, Oost-Vlaanderen 9000, Belgium
  • UZ Gasthuisberg ( Site 0102)
    Leuven, Vlaams-Brabant 3000, Belgium
  • AZ Groeninge ( Site 0105)
    Kortrijk, West-Vlaanderen 8500, Belgium
  • Dr. Everett Chalmers Regional Hospital ( Site 0204)
    Fredericton, New Brunswick E3B 5N5, Canada
  • Moncton Hospital - Horizon Health Network ( Site 0201)
    Moncton, New Brunswick E1C 6Z8, Canada
  • Princess Margaret Cancer Centre ( Site 0209)
    Toronto, Ontario M5G 1X6, Canada
  • Hopital Cite de la Sante de Laval ( Site 0203)
    Laval, Quebec H7M 3L9, Canada
  • McGill University Health Centre ( Site 0207)
    Montreal, Quebec H4A 3J1, Canada
  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0202)
    Sherbrooke, Quebec J1H 5N4, Canada
  • Centro Investigación del Cáncer James Lind ( Site 0251)
    Temuco, Araucania 4780000, Chile
  • Sociedad Oncovida S.A. ( Site 0250)
    Santiago, Region M. De Santiago 7510032, Chile
  • Clínica San Carlos de Apoquindo Red Salud UC Christus ( Site 0252)
    Santiago, Region M. De Santiago 7620002, Chile
  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0353)
    Valledupar, Cesar 200001, Colombia
  • Oncomedica S.A. ( Site 0352)
    Monteria, Cordoba 230002, Colombia
  • Administradora Country SA - Clinica del Country ( Site 0350)
    Bogota, Distrito Capital De Bogota 110221, Colombia
  • Instituto Nacional de Cancerologia E.S.E ( Site 0362)
    Bogota, Distrito Capital De Bogota 110321, Colombia
  • Oncologos del Occidente ( Site 0364)
    Pereira, Risaralda 660001, Colombia
  • Fundacion Cardiovascular de Colombia ( Site 0360)
    Bucaramanga, Santander 681002, Colombia
  • Hemato Oncologos S.A. ( Site 0355)
    Cali, Valle Del Cauca 760042, Colombia
  • C.H.U. de Strasbourg Hopital de Hautepierre ( Site 0464)
    Strasbourg, Bas-Rhin 67098, France
  • Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0455)
    Saint-Herblain, Bretagne 44805, France
  • CHU Jean Minjoz ( Site 0450)
    Besancon, Doubs 25000, France
  • CHU Bordeaux Haut-Leveque ( Site 0457)
    Pessac Cedex, Gironde 33604, France
  • CHU Saint Eloi ( Site 0467)
    Montpellier, Herault 34295, France
  • Centre Leon Berard ( Site 0459)
    Lyon, Rhone-Alpes 69008, France
  • Hopital Europeen Georges Pompidou ( Site 0452)
    Paris, 75015, France
  • Universitaetsklinikum Ulm ( Site 0500)
    Ulm, Baden-Wurttemberg 89081, Germany
  • St. Josef und St. Elisabeth Hospital gGmbH-Hematology, oncology and palliative medicine ( Site 0503)
    Bochum, Nordrhein-Westfalen 44791, Germany
  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0504)
    Berlin, 10117, Germany
  • Facharztzentrum Eppendorf ( Site 0501)
    Hamburg, 20249, Germany
  • Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 1432)
    Gyula, Bekes 5700, Hungary
  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás Ce
    Miskolc, Borsod-Abauj-Zemplen 3526, Hungary
  • Debreceni Egyetem Klinikai Kozpont ( Site 1426)
    Debrecen, Hajdu-Bihar 4032, Hungary
  • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1427)
    Szolnok, Jasz-Nagykun-Szolnok 5000, Hungary
  • Zala Megyei Szent Rafael Korhaz ( Site 1429)
    Zalaegerszeg, Zala 8900, Hungary
  • Orszagos Onkologiai Intezet ( Site 1431)
    Budapest, 1122, Hungary
  • Aichi Cancer Center Hospital ( Site 0658)
    Nagoya, Aichi 464-8681, Japan
  • National Cancer Center Hospital East ( Site 0650)
    Kashiwa, Chiba 2778577, Japan
  • National Hospital Organization Shikoku Cancer Center ( Site 0652)
    Matsuyama, Ehime 791-0280, Japan
  • St. Marianna University School of Medicine Hospital ( Site 0657)
    Kawasaki, Kanagawa 216-8511, Japan
  • Saitama Cancer Center ( Site 0653)
    Kitaadachi-gun, Saitama 362-0806, Japan
  • Shizuoka Cancer Center Hospital and Research Institute ( Site 0655)
    Sunto-gun, Shizuoka 411-8777, Japan
  • Chiba Cancer Center ( Site 0656)
    Chiba, 260-8717, Japan
  • National Hospital Organization Kyushu Cancer Center ( Site 0654)
    Fukuoka, 811-1395, Japan
  • National Cancer Center Hospital ( Site 0651)
    Tokyo, 104-0045, Japan
  • The Cancer Institute Hospital of JFCR ( Site 0659)
    Tokyo, 135-8550, Japan
  • Asan Medical Center ( Site 0952)
    Songpagu, Seoul 05505, Korea, Republic of
  • Kyungpook National University Chilgok Hospital ( Site 0956)
    Daegu, Taegu-Kwangyokshi 41404, Korea, Republic of
  • Korea University Anam Hospital ( Site 0955)
    Seoul, 02841, Korea, Republic of
  • Seoul National University Hospital ( Site 0950)
    Seoul, 03080, Korea, Republic of
  • Severance Hospital Yonsei University Health System ( Site 0951)
    Seoul, 03722, Korea, Republic of
  • Samsung Medical Center ( Site 0954)
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea St. Mary s Hospital ( Site 0953)
    Seoul, 06591, Korea, Republic of
  • Daugavpils Regional Hospital ( Site 1502)
    Daugavpils, 5417, Latvia
  • P. Stradina Clinical University Hospital ( Site 1500)
    Riga, LV-1002, Latvia
  • Riga East Clinical University Hospital ( Site 1501)
    Riga, LV-1079, Latvia
  • LSMUL Kauno Klinikos ( Site 1528)
    Kaunas, 50161, Lithuania
  • Nacionalinis Vezio Institutas ( Site 1527)
    Vilnius, 08406, Lithuania
  • Vilniaus Universiteto Ligonine Santaros Klinikos ( Site 1526)
    Vilnius, 08460, Lithuania
  • Arkhangelsk Clinical Oncological Dispensary ( Site 1113)
    Arkhangelsk, Arkhangel Skaya Oblast 163045, Russian Federation
  • GBUZ Republican Clinical Oncological Dispensary-Antitumor drug therapy department ( Site 1130)
    Ufa, Baskortostan, Respublika 450054, Russian Federation
  • Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 1121)
    Krasnoyarsk, Krasnoyarskiy Kray 660133, Russian Federation
  • MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 1129)
    Krasnogorsk, Moskovskaya Oblast 143442, Russian Federation
  • National Medical and Surgical Center n.a. N.I.Pirogov ( Site 1126)
    Moscow, Moskva 105203, Russian Federation
  • N.N. Blokhin NMRCO ( Site 1106)
    Moscow, Moskva 115478, Russian Federation
  • First Moscow State Medical University n.a. I.M.Sechenov ( Site 1127)
    Moscow, Moskva 119991, Russian Federation

Showing the first 100 of 129 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Takashima A, Garcia-Alfonso P, Manneh R, Besen AA, Hong YS, Cuyle PJ, Yanez P, Burge M, Yoshino T, Kim TW, Cui K, Li C, Jain R, Adelberg D, Taieb J. Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. Eur J Cancer. 2024 Jul;205:114036. doi: 10.1016/j.ejca.2024.114036. Epub 2024 Mar 21. PubMed 38749110 ↗
  • Kim TW, Taieb J, Gurary EB, Lerman N, Cui K, Yoshino T. Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. Future Oncol. 2021 Dec;17(36):5013-5022. doi: 10.2217/fon-2021-0899. Epub 2021 Nov 15. PubMed 34779646 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Mar 2023, 31 months.

Results were first posted in Apr 2024, 1 year after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 31 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2020
First posted
Jul 2, 2020
StartActual
Aug 19, 2020
Primary completionActual
Mar 27, 2023
CompletionActual
Nov 6, 2023
Results first posted
Apr 2, 2024
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04456699
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jul 2, 2020
Start date
Aug 19, 2020
Primary completion
Mar 27, 2023
Completion
Nov 6, 2023
Results posted
Apr 2, 2024
Last update
Oct 29, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olaparib · Bevacizumab

Start the discussion